Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients | MicrobiomeTrials← Back to trialsNCT02763644
Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients
TERMINATEDPHASE2INTERVENTIONAL
Trial Details
Start: 2016-04-22Est. Completion: 2017-02-10
Enrollment target: 7 participants Locations- Novartis Investigative Site, Chapel Hill, North Carolina, United States
- Novartis Investigative Site, Columbus, Ohio, United States
- Novartis Investigative Site, Paris, Cedex 10, France
- Novartis Investigative Site, Marseille, France
- Novartis Investigative Site, Hamburg, Germany
- Novartis Investigative Site, Heidelberg, Germany
Other microbiome trials you might be interested in
Transplant Associated Microangiopathy TAMTransplant Complication
The goal of this observational study is to learn about the incidence of Transplant Associated Thrombotich Microangiopath…
Birmingham, United StatesEst. completion Feb 2028
GVHD - Graft-Versus-Host DiseaseInfections After HSCTTransplant Associated Microangiopathy TAMSinusoidal Obstruction Syndrome (SOS)HSCT Engraftment
Allogeneic hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for people with severe blood-relate…
Milan, Italy
Est. completion Dec 31, 2026